Quelle place pour la radiothérapie et la chimiothérapie dans le traitement adjuvant des carcinomes urothéliaux des voies excrétrices urinaires supérieures ?

Gustin, P.; Yossi, S.; Lafont, M.; Peyraga, G.; Trémolières, P.; Rousseau, D.; Cellier, P.; Paumier, A.; Martin, F.; Chapet, O.; Mesgouez-Nebout, N.

doi:10.1016/j.canrad.2014.11.012

Cited by 5 publications

(3 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…2 As RCC is resistant to traditional chemotherapy, radiation therapy or hormonal therapy, further investigation of the molecular mechanisms underlying RCC tumorigenesis and progression is crucial for individual treatment of RCC. 3 Since the discovery of the mTOR signaling pathway, there have been many studies focusing on the regulatory role of the mTOR signaling pathway on tumors. 4,5 Inhibitors targeting the mTOR signaling pathway have been widely used in advanced RCC treatment.…”

Section: Introductionmentioning

confidence: 99%

<p>ITPKA1 Promotes Growth, Migration and Invasion of Renal Cell Carcinoma via Activation of mTOR Signaling Pathway</p>

Zhu¹,

Zhang

et al. 2020

OTT

View full text Add to dashboard Cite

Background: Renal cell cancer (RCC) is one of the most lethal malignancies of the kidney in adults. mTOR (mammalian target of rapamycin) signaling pathway plays a pivotal role in RCC tumorigenesis and progression and inhibitors targeting the mTOR pathway have been widely used in advanced RCC treatment. Therefore, it is of great significance to explore the potential regulators of the mTOR pathway as RCC therapeutic targets. Materials and Methods: Bioinformatics analysis was used to screen out the most significant differentially expressed genes in the RCC dataset of The Cancer Genome Atlas (TCGA). Real-time PCR and Western-blot analysis were utilized to examine the expression of inositol-1,4,5-trisphosphate-3-kinase-A (ITPKA) in four RCC cell lines and one human embryonic kidney cell line. Cell counting Kit-8 and colony formation assay were performed to estimate the effect of ITPKA on the proliferation ability of RCC cells. Wound healing and Transwell assays were used to test the effect of ITPKA on RCC cell migration and invasion. Xenograft formation assay was performed in nude mice to investigate the effect of ITPKA in vivo. mTORC1 pathway inhibitor was added to explore the mechanisms by which ITPKA regulates RCC cell growth and progression. Results: Based on bioinformatics analysis, ITPKA is screened out as one of the most significant differentially expressed genes in RCC. ITPKA is upregulated and positively correlated with RCC malignancy and poorer prognosis. ITPKA promotes RCC growth, migration and invasion in cultured cells, and accelerates tumor growth in nude mice. Mechanistically, ITPKA stimulates the mTORC1 signaling pathway which is a requirement for ITPKA modulation of RCC cell proliferation, migration and invasion. Conclusion: Our data demonstrate a critical regulatory role of the ITPKA in RCC and suggest that ITPKA/mTORC1 axis may be a promising target for diagnosis and treatment of RCC.

show abstract

Section: Introductionmentioning

confidence: 99%

<p>ITPKA1 Promotes Growth, Migration and Invasion of Renal Cell Carcinoma via Activation of mTOR Signaling Pathway</p>

Zhu¹,

Zhang

et al. 2020

OTT

View full text Add to dashboard Cite

show abstract

“…Some patients do not undergo radical nephroureterectomy due to advanced age, comorbidities, or intolerance or refusal of the procedure ( 3 ). In addition, locoregional urothelial malignancies of urinary tract was treated by adjuvant radiotherapy or combined with chemotherapy ( 5 , 11 , 12 ), and confocal laser endomicroscopy has been used for upper tract urothelial carcinoma ( 13 , 14 ), although radiotherapy is rarely used for ureter tumors.…”

Section: Discussionmentioning

confidence: 99%

“…For example, adjuvant radiotherapy in the setting of locally advanced ureteral carcinoma improves locoregional control following definitive surgery ( 4 ). However, in ureteral lesions often close to intestines, spinal cord, and blood vessels, long-term high-dose radiotherapy may result in intestinal injury, spinal cord damage, or retroperitoneal fibrosis ( 5 ). As a novel kind of radiotherapy, intraluminal brachytherapy with radioactive iodine-125 seed strand has been used in some malignant tumors patients who cannot undergo or refuse surgical resection and shows encouraging efficacy ( 6 ), including advanced/recurrent esophageal cancer ( 7 ), malignant biliary obstruction ( 8 ), and hepatocellular carcinoma with portal vein tumor thrombus ( 9 ).…”

Section: Introductionmentioning

confidence: 99%

Safety and efficacy of iodine-125 seed strand for intraluminal brachytherapy on ureteral carcinoma

Jiao

Zhang

et al. 2023

Front. Oncol.

View full text Add to dashboard Cite

ObjectiveOur aim is to evaluate the safety and efficacy of iodine-125 seed strand for intraluminal brachytherapy on ureteral carcinoma.MethodsFrom November 2014 to November 2021, 22 patients with ureteral cancer not suitable for surgical resection were enrolled. Iodine-125 seed strand was inserted under c-arm CT and fluoroscopic guidance. The technical success rate, complications, disease control rate, and survival time were evaluated. Hydronephrosis Girignon grade and ureteral cancer sizes before and after treatment were compared.ResultsA total of 46 seed strands were successfully inserted and replaced, with a technical success rate of 100% and median procedure time of 62 min. No procedure-related death, ureteral perforation, infection, or severe bleeding occurred. Minor complications were observed in eight (36.4%) patients, and migration of seed strand was the most common complication. Six months after seed strand brachytherapy, one complete response, three partial responses, and five stable diseases were evaluated, and the disease control rate was 64.3%. The Girignon grade of hydronephrosis was significantly improved 1 to 3 months after seed strand insertion. Disease control rates were 94.4, 62.5, and 64.3% at 1-, 3-, and 6-month follow-up. Twenty patients were successfully followed up, with a mean follow-up of 18.0 ± 14.5 months. The median overall survival and progress-free survival were 24.7 and 13.0 months, respectively.ConclusionIodine-125 seed strand is safe and effective for intraluminal brachytherapy and can be used as an alternative to patients with ureteral carcinoma who are not suitable for surgical resection or systemic combined therapy.

show abstract

Carcinome neuroendocrine à petites cellules des voies urinaires excrétrices supérieures : à propos d’un cas

Beddok

Vanbocksteal

Rakotonavalona

et al. 2016

Cancer/Radiothérapie

View full text Add to dashboard Cite

Quelle place pour la radiothérapie et la chimiothérapie dans le traitement adjuvant des carcinomes urothéliaux des voies excrétrices urinaires supérieures ?

Cited by 5 publications

References 41 publications

<p>ITPKA1 Promotes Growth, Migration and Invasion of Renal Cell Carcinoma via Activation of mTOR Signaling Pathway</p>

<p>ITPKA1 Promotes Growth, Migration and Invasion of Renal Cell Carcinoma via Activation of mTOR Signaling Pathway</p>

Safety and efficacy of iodine-125 seed strand for intraluminal brachytherapy on ureteral carcinoma

Carcinome neuroendocrine à petites cellules des voies urinaires excrétrices supérieures : à propos d’un cas

Contact Info

Product

Resources

About